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Abstract Vascular endothelial cells respond to external stimuli
by altering the secretion of several bioactive molecules, including
von Willebrand factor (vWf), prostacyclin (PGI2) and nitric
oxide (NO). The release of all three molecules is regulated by a
rise in cytosolic calcium ([Ca2+]i). In the present study we
investigated whether cAMP-dependent signaling provides differ-
ential regulation of these effector systems by modulating the
effect of [Ca2+]i in cultured human endothelial cells. The stable
PGI2 analog iloprost, like other cAMP-raising agents (forskolin
and adenosine), caused an acute dose-dependent increase in vWf
release and potentiated the secretory response to thrombin. In
contrast, iloprost, forskolin and adenosine failed to induce PGI2
release and inhibit thrombin-induced release. Our findings
indicate cAMP-raising agents have opposite effects on [Ca2+]i-
mediated vWf secretion and PGI2 release. PGI2 may potentiate
vWf release and inhibit its own release in an autocrine manner.
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1. Introduction
Vascular endothelial cells respond to external stimuli by
altering the secretion of several bioactive molecules, including
von Willebrand factor (vWf), prostacyclin (PGI2) and nitric
oxide (NO). vWf is released by exocytosis from specialized
secretory granules called Weibel-Palade bodies [1]. Exocytosis
in response to thrombin and several other agonists is mediated
by a rise in cytosolic calcium ([Ca2]i) and activation of a
calmodulin-dependent signaling pathway [2]. vWf release can
also be induced by phorbol esters, suggesting a role for pro-
tein kinase C (PKC). However, thrombin-induced vWf release
is not prevented by PKC inhibitors [3]. Thus, a rise in [Ca2]i
is thought to be the main signaling event for exocytosis. Pros-
tacyclin production, via the activation of phospholipase A2, is
also a calcium-dependent process. In addition it is modulated
by protein tyrosine kinases and possibly by PKC [4,5]. NO
synthesis is also driven by a rise in [Ca2]i. Calcium/calmodu-
lin directly binds endothelial nitric oxide synthase (eNOS) and
stimulates NO synthesis in the vicinity of the plasma mem-
brane, where eNOS is associated with discrete membrane
structures called caveolae [6]. Thus, a rise in [Ca2]i is a key
signaling event for three di¡erent e¡ector systems in a single
cell type. Given the di¡erent physiological functions of these
e¡ector systems, it is very likely that they are regulated in a
di¡erential manner. Such di¡erential regulation could be ac-
counted for in part by di¡erent subcellular localization of the
calcium signal or by specialization of endothelial cells in dif-
ferent vascular beds. However, additional signaling pathways
may provide di¡erential regulation by modulating the e¡ect of
[Ca2]i.
We have recently observed that vWf secretion is also regu-
lated by cAMP. Pharmacological agents such as forskolin and
8-bromo-cAMP can induce vWf secretion, and strongly po-
tentiate the secretory response to thrombin [7]. Furthermore,
the receptor-mediated agonists epinephrine and adenosine po-
tentiate the response to [Ca2]i-raising agents such as throm-
bin and ATP, in a cAMP-dependent manner [7,8]. Prostacy-
clin produced by endothelial cells acts via a speci¢c, adenylate
cyclase-coupled receptor [9]. Prostacyclin is thought to regu-
late endothelial permeability via a cAMP-dependent signaling
pathway, suggesting a role for prostacyclin in the autocrine
regulation of endothelial function [10]. In the present study we
investigated the e¡ect of prostacyclin, using its stable analog
iloprost, on vWf secretion and on prostacyclin production in
cultured human endothelial cells. In addition, since endothe-
lial NO is also an autocrine regulator of endothelial function,
we tested the e¡ect of NO on vWf secretion.
2. Materials and methods
2.1. Materials
RPMI 1640 was from Gibco BRL (Gaithersburg, MD, USA), fetal
calf serum (FCS) and collagenase were from Seromed (Berlin, Ger-
many). Endothelial cell growth supplement (ECGS) was from Upstate
Biotechnology Inc. (Lake Placid, NY, USA). Anti-vWf antibodies
were from Dako (Glostrup, Denmark). Iloprost was from Shering
(Berlin, Germany). Adenosine was from Fluka (Buchs, Switzerland).
Linsidomine (SIN-1) and sodium nitroprusside were from RBI (Na-
tick, MA, USA). Human thrombin, 3-isobutyl-1-methyl-xanthine
(IBMX) and forskolin were from Sigma (St. Louis, MO, USA).
2.2. Cell culture
Primary cultures of endothelial cells (HUVECs) were obtained from
individual human umbilical veins by collagenase digestion as de-
scribed previously [11]. They were grown in medium RPMI 1640
supplemented with 10% FCS, 90 Wg/ml heparin and 15 Wg/ml
ECGS. Cells were used during passages 1 or 2. Tissue culture dishes
as well as the multiwell plates (Costar, Cambridge, MA, USA) were
coated with 0.1% gelatin.
2.3. vWf release studies
Con£uent monolayers of HUVECs grown in 24-well dishes were
washed three times and preincubated in Krebs-Ringer-bicarbonate
bu¡er (KRBH, 120 mmol/l NaCl, 4.75 mmol/l KCl, 1.2 mmol/l
KH2PO4, 0.6 mmol/l MgSO4, 1.2 mmol/l CaCl2, 25 mmol/l NaHCO3,
25 mmol/l HEPES, pH 7.4) supplemented with 0.1% BSA, and pre-
incubated for 5^10 min at 37‡C. After a fourth wash, cells were in-
cubated in KRBH with the di¡erent agents. The collected superna-
tants were cleared of cell debris by centrifugation (16 000Ug for 60 s)
and stored at 320‡C for later assay. All pharmacological agents were
directly dissolved in the incubation medium, only forskolin and
IBMX were dissolved in DMSO. The ¢nal concentration of DMSO
in the incubation medium did not exceed 0.2%, a concentration which
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has no e¡ect on vWf release. vWf was measured in the supernatants
by ELISA as described previously [12]. A standard curve was con-
structed from serial dilutions of normal pooled plasma, assuming a
plasma concentration of 10 Wg/ml. Results are usually expressed in ng/
well/time unit.
2.4. Prostacyclin release studies
Con£uent HUVECs grown in 12-well dishes were washed three
times in KRBH and incubated at 37‡C in 1.2 ml KRBH. After 10
min, 0.6 ml was gently removed. The various agonists were then
added with minimal shaking. The incubation was continued for the
indicated times, and the supernatants were collected for later assays.
For both vWf and PGI2, release was calculated as the di¡erence in
content between the two successive samples. This procedure was used
to minimize the possible e¡ect of mechanical stress (due to cell han-
dling) on PGI2 release.
vWf was measured by ELISA. PGI2 was measured by a speci¢c
radioimmunoassay of its stable metabolite 6-keto-PGF1K as previ-
ously described [13]. The agonists tested, in particular iloprost, did
not interfere with the immune reaction when added to standard sam-
ples. We observed considerable variation in basal PGI2 release be-
tween cell batches. The results were therefore expressed in relative
values, i.e. as a percentage of release from cells stimulated with throm-
bin (0.5 U/ml) from the same cell preparation. Unless indicated oth-
erwise, results are shown as mean þ S.E.M. Statistical analysis was
done using the two-tailed, paired Student’s t-test.
3. Results
3.1. E¡ect of iloprost on vWf release from cultured HUVECs
To investigate the e¡ect of prostacyclin on vWf release we
employed the stable analog iloprost on vWf release from cul-
tured HUVECs (Fig. 1). Iloprost (1 nmol/l to 1 Wmol/l) added
for 30 min caused a 1.4-fold increase (from 2.5 þ 0.6 to
3.4 þ 0.6 ng/well/30 min, P = 0.04, n = 5) at the highest concen-
tration. Addition of IBMX alone (100 Wmol/l), which blocks
cAMP degradation by inhibiting nucleotide phosphodiester-
ases, had no e¡ect on vWf release. However, when added
together with IBMX, the secretory response to iloprost was
clearly potentiated. The maximal response (at 1 Wmol/l) was a
2.5-fold increase in vWf release (from 2.7 þ 0.6 to 6.7 þ 1.1 ng/
well/30 min, P = 0.02), and there was a shift to the left in the
dose-response curve, with a secretory response detectable at
concentrations of iloprost as low as 10 nmol/l (P = 0.01, n = 5).
We also observed a potentiating e¡ect of iloprost on throm-
bin-induced vWf release. Indeed, the secretory response to
thrombin and iloprost added together was greater than the
sum of the responses to either agent added alone. Iloprost
(1 Wmol/l) caused an increase in vWf release from 9.2 þ 1.2
to 13.9 þ 2.0 ng/well/30 min (P = 0.01) when added to throm-
bin and from 15.3 þ 2.5 to 27.0 þ 3.8 ng/well/30 min (P = 0.01)
when added to thrombin and IBMX.
We next performed a comparative time course study of
iloprost- and thrombin-induced vWf secretion (Fig. 2). The
response to thrombin was rapid, reaching signi¢cance already
after 5 min, the earliest time point studied. In contrast, ilo-
prost-induced vWf release could be demonstrated only after
10 and 30 min (P6 0.05 for both time points). The addition of
IBMX potentiated the response to iloprost but failed to alter
the time course: a signi¢cant but small response was observed
after 10 min, and became more obvious only at later time
points. This delayed secretory response to iloprost is highly
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Fig. 1. E¡ect of iloprost on vWf release: dose response. Con£uent
HUVECs grown in 24-well plates were incubated for 30 min at
37‡C with increasing concentrations of iloprost (0.001^1 Wmol/l)
added alone (squares), or together with 100 Wmol/l IBMX (circles),
0.5 U/ml thrombin (upwards triangles) or IBMX and thrombin
combined (downwards triangles). vWf release was measured in the
supernatant by ELISA. Results are shown as the mean þ S.E.M. of
¢ve experiments. *P6 0.05 compared to unstimulated control cells.
Fig. 2. Iloprost-induced vWf release: time course. Con£uent HU-
VECs grown in 24-well plates were incubated for the indicated times
with 1 Wmol/l iloprost, alone (circles) or together with 100 Wmol/l
IBMX (downwards triangles), or 0.5 U/ml thrombin (diamonds).
Control wells were incubated with KRBH alone (squares) or 100
Wmol/l IBMX (upwards triangles). vWf release was measured in the
supernatant by ELISA. Results are the mean þ S.E.M. of ¢ve experi-
ments. *P6 0.05 compared to unstimulated control cells.
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reminiscent of our previous studies with other cAMP-raising
agents such as forskolin and adenosine.
Thrombin has been reported to induce PGI2 release from
cultured endothelial cells. We therefore wondered whether
PGI2 released into the incubation bu¡er could mediate in
part the secretory response to thrombin. However, throm-
bin-induced vWf release was not a¡ected by preincubation
with the cyclooxygenase inhibitor indomethacin (1^10 Wmol/
l, added for 10^40 min) (not shown).
3.2. E¡ect of cAMP-raising agents on vWf secretion and
PGI2 release
To compare the e¡ect of cAMP-raising agents on vWf se-
cretion and PGI2 release, we optimized the incubation condi-
tions to measure both secretory products from the same cell
preparation. HUVECs were preincubated for 10 min in 1.2 ml
KRBH. After removal of 0.6 ml incubation bu¡er, the cAMP-
raising agents and thrombin were added for 20 min (Fig. 3).
As previously reported [7], forskolin ( þ IBMX) induced vWf
release, and potentiated the secretory response to thrombin
(Fig. 3A). In contrast, PGI2 release was not reliably detectable
in unstimulated cells, and was not stimulated by forskolin.
Thrombin-induced PGI2 release was inhibited by both 100
Wmol/l IBMX (354 þ 14%, P = 0.01, n = 5) and 10 Wmol/l for-
skolin (333 þ 7%, P = 0.01, n = 5). Addition of the two agents
combined inhibited thrombin-induced PGI2 release by
76 þ 6% (P6 0.01, n = 5). These ¢ndings strongly suggest
that increased cellular cAMP inhibits thrombin-induced
PGI2 release. We also attempted to test the e¡ect of the
cAMP analog 8-bromo-cAMP, but unexpectedly this com-
pound interfered with the PGI2 assay. Since adenosine induces
vWf release in a cAMP-dependent mechanism [8], we com-
pared the e¡ect of adenosine on vWf and PGI2 release (Fig.
3B). Adenosine both in the absence or presence of IBMX
induced vWf release and potentiated the response to throm-
bin, in agreement with our earlier report [8]. Similar to the
pattern seen with forskolin, adenosine failed to induce PGI2
release, and inhibited thrombin-induced PGI2 release by
29 þ 7% (P = 0.03, n = 4) when added alone and by 62 þ 4%
(P = 0.001, n = 4) when added together with IBMX.
3.3. E¡ect of iloprost on thrombin-induced PGI2 release
The present data with forskolin, IBMX and adenosine in-
dicate that thrombin-induced PGI2 release can be inhibited by
a rise in cellular cAMP content. Since PGI2 itself is a cAMP-
raising agent, our ¢ndings raise the possibility that PGI2 in-
hibits its own release in an autocrine manner. To test this
hypothesis, we compared the e¡ect of iloprost on vWf secre-
tion and PGI2 release (Fig. 4). Iloprost or IBMX was added
for 20^40 min prior to a 10 min stimulation with thrombin.
Iloprost, alone or in the presence of IBMX, again caused vWf
secretion and potentiated thrombin-induced vWf release. In
contrast, iloprost caused a 35 þ 9% inhibition of thrombin-
induced PGI2 release (P = 0.02, n = 5). The inhibitory e¡ect
of IBMX was even stronger than in the previous experiments
(with a 71 þ 7% inhibition), likely due to the longer preincu-
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Fig. 3. Di¡erential regulation of vWf secretion and PGI2 release by cAMP-raising agents. Con£uent HUVECS grown in 12-well plates were in-
cubated at 37‡C in 1.2 ml KRBH. After 10 min, a ¢rst 0.6 ml sample was gently removed. IBMX (100 Wmol/l), forskolin (For, 10 Wmol/l), ad-
enosine (Ado, 100 Wmol/l) and thrombin (Thr, 0.5 U/ml) were then added as indicated. The incubation was continued for 20 min and the
supernatants collected for vWf and PGI2 assay. For both parameters, release was calculated as the di¡erence in content between the two suc-
cessive samples, and expressed as a percentage of the response to thrombin alone. Results with forskolin (A) and adenosine (B) derive from
two distinct sets of experiments. Results are the mean þ S.E.M. of ¢ve experiments. *P6 0.05 compared to unstimulated control cells.
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bation time. However, the inhibitory e¡ect of iloprost and
IBMX combined was still even more pronounced (81 þ 5%
inhibition), reaching statistical signi¢cance when compared
to both thrombin alone or to thrombin/IBMX (P6 0.05,
n = 5).
3.4. E¡ect of NO donors on thrombin-induced vWf release
We investigated whether activation of a cGMP-dependent
pathway could modulate vWf release in cultured HUVECs.
We tested two NO donors, linsidomine (SIN-1) and sodium
nitroprusside (SNP). Both agents failed to in£uence basal or
thrombin-stimulated vWf release (Fig. 5). Similar negative
results were obtained using the cell-permeant cGMP analogs
8-bromo-cGMP or Sp-8-CPT-cGMPS.
4. Discussion
Our earlier studies have demonstrated that a cAMP-de-
pendent signaling pathway is involved in the control of regu-
lated vWf release from cultured HUVECs. Forskolin, an ac-
tivator of adenylate cyclase, and the cAMP analog 8-bromo-
cAMP both induce vWf release and potentiate the secretory
response to thrombin [7]. These responses are potentiated by
co-incubation with IBMX, an inhibitor of phosphodiesterases
which blocks cAMP degradation. Similar responses were ob-
served with receptor-mediated cAMP-raising agents such as
epinephrine and adenosine [7,8]. The e¡ect of cAMP-raising
agents is due to regulated release from Weibel-Palade bodies,
as indicated by its rapid time course (6 30 min). Furthermore,
vWf secreted in response to forskolin consists of high molec-
ular weight multimers, typical of regulated release (U.M.
Vischer, unpublished observations). Although the secretory
responses we observed with receptor-mediated agonists (epi-
nephrine, adenosine) were small, cAMP-dependent vWf secre-
tion is likely to be of physiological signi¢cance. Indeed, in
humans epinephrine infusion causes a rise in circulating vWf
levels [14]. Further, the rise in plasma vWf levels associated
with physical activity in healthy subjects is inhibited by the L-
adrenoceptor blocker propranolol [15].
The main ¢nding of the present study is that iloprost, a
prostacyclin agonist known to increase cellular cAMP content
[9], also induced vWf secretion in cultured HUVECs, either
when added alone or in combination with IBMX. Moreover,
iloprost potentiated the secretory response to thrombin. The
secretory response to iloprost is slower than to thrombin, but
still occurred within 30 min, indicating secretion from a pre-
formed store rather induction of vWf synthesis and constitu-
tive release. From a physiological point of view, it is unex-
pected that cAMP-mediated signaling activated by adenosine
and prostacyclin stimulates vWf secretion in the endothelium,
while it inhibits platelet activation (and by inference vWf re-
lease from K-granules). However, exocytosis evoked by cAMP
(alone and/or in synergism with intracellular calcium) is not
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Fig. 4. E¡ect of iloprost on vWf secretion and PGI2 release. Con£u-
ent HUVECS grown in 12-well plates were incubated at 37‡C in 1.2
ml KRBH. After 10 min, a ¢rst 0.6 ml sample was gently removed.
IBMX (100 Wmol/l) and iloprost (Ilo, 1 Wmol/l) were then added as
indicated. The incubation was continued for 30^50 min, and throm-
bin was added for the last 10 min. vWf and PGI2 release into the
supernatant were measured by ELISA. For both parameters, release
was calculated as the di¡erence in content between the two succes-
sive samples, and expressed as a percentage of the response to
thrombin alone. Results are the mean þ S.E.M. of ¢ve experiments.
*P6 0.05 compared to unstimulated control cells.
Fig. 5. E¡ect of NO donors on vWf release. Con£uent HUVECs
grown in 24-well plates were incubated for 30 min at 37‡C in the
presence of 1 mM sodium nitroprusside (SNP) or 1 mM linsidomine
(SIN-1). Thrombin at various concentrations was added for the last
10 min (four experiments) or for the whole 30 min incubation (two
experiments). Given the lack of di¡erences the results of the six ex-
periments were pooled for calculations, and are shown as mean þ
S.E.M.
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surprising since it has been observed in many secretory cell
systems, such as insulin-secreting L-cells [16], the exocrine
pancreas [17] and others. Our observations are compatible
with rat hindlimb perfusion studies showing a potentiating
e¡ect of forskolin on vWf secretion induced by the calcium-
mobilizing agents bradykinin and platelet-activating factor
[18].
Prostacyclin infusion is used in the treatment of Raynaud’s
disease [19] and of primary pulmonary hypertension (PPH)
[20]. In the case of PPH, treatment is associated with a
marked decrease in vWf levels, as well as a decrease in other
endothelial markers such as t-PA and PAI-1 [20,21]. The
present data suggest that prostacyclin does not decrease vWf
levels by a direct e¡ect on endothelial vWf release. The e¡ect
of prostacyclin is more likely to be due to an indirect e¡ect,
such as improved vessel perfusion secondary to its hemody-
namic e¡ect, resulting in decreased shear stress [22]. An direct
inhibitory e¡ect on platelet vWf release is also a possibility.
vWf secretion, PGI2 and NO release are all induced by an
increase in [Ca2]i, raising the issue of the di¡erential regula-
tion of these e¡ector systems. Our ¢ndings demonstrate that
while cAMP-mediated signaling induces vWf release, it inhib-
its PGI2 release from cultured HUVECs. This opposite e¡ect
was observed in response to forskolin, adenosine and Iloprost.
Previous studies have suggested an inhibitory action of cAMP
on PGI2 release. However, this conclusion was based solely on
the inhibitory e¡ect of IBMX [23]. It is now strengthened by
our results with the receptor-mediated cAMP-raising agents
Iloprost and adenosine. Our observations imply that PGI2 can
inhibit its own release from endothelial cells, in an autocrine
manner. The inhibitory e¡ect of IBMX on PGI2 release is
greater than that of other cAMP-raising agents. For instance,
the e¡ect of IBMX on PGI2 release was greater than that of
forskolin, while the e¡ect of these two agents on cAMP cel-
lular content is a 2-fold and 4-fold increase respectively [7]. A
possible explanation is that IBMX raises not only cAMP but
also cGMP levels (by inhibition of cGMP degradation) [24],
which could be involved in the regulation of PGI2 release. We
did not pursue this hypothesis given the limitations of our
culture system for the investigation of cGMP-mediated signal-
ing (see below).
The possible e¡ects of nitric oxide/cGMP-dependent signal-
ing on vWf release are an unsettled issue. Using a rat hind-
limb perfusion system, Tranquille and Emeis reported an in-
hibitory e¡ect of sodium nitroprusside and atrial natriuretic
peptide ^ but not of 8-bromo-cGMP ^ on vWf and t-PA
release [18]. In cat coronary artery segments, thrombin-in-
duced endothelial exocytosis could be inhibited by endothe-
lin-1 in an NO-dependent manner [25]. In contrast, exercise-
induced increases in plasma vWf levels in healthy humans
appear to be mediated in part by NO, since they are inhibited
by the NO synthase inhibitor L-NMMA [26]. We failed to
observe an e¡ect of either NO donors or 8-bromo-cGMP
on vWf release in cultured HUVECs. However, this negative
result does not exclude a role for NO-mediated signaling in
vWf release. Indeed, in contrast to aortic endothelial cells,
HUVECs do not express cGMP-dependent protein kinase
type I, the activation of which is thought to inhibit throm-
bin-induced calcium mobilization [27]. These cells thus appear
to be insensitive to an inhibitory e¡ect of NO-dependent sig-
naling on vWf release.
In summary, our results demonstrate that the prostacyclin
analog iloprost, like other cAMP-raising agents, induces vWf
release from cultured HUVECs, and potentiates thrombin-in-
duced vWf release. This is a selective e¡ect since cAMP-rais-
ing agents ^ including iloprost ^ inhibit PGI2 release. The
latter ¢nding suggests that PGI2 can inhibit its own release
in an autocrine manner and provides a mechanism for the
di¡erential regulation of two endothelial calcium-dependent
e¡ector systems.
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